Investment Thesis
Arcutis faces significant fundamental challenges despite modest revenue growth, with persistent operating losses (-3.3% margin) and negative free cash flow (-6.3M) indicating the company is burning cash to fund operations. The negative interest coverage ratio (-1.6x) suggests inability to service debt from operations, while modest revenue growth of 1.1% YoY fails to demonstrate meaningful commercial traction in a capital-intensive pharmaceutical sector.
ARQT Strengths
- Strong liquidity position with 3.17x current ratio and 42.9M in cash providing near-term runway
- Improved net loss trajectory with 88.5% YoY improvement in net income suggesting operational leverage emerging
- Moderate debt-to-equity ratio of 0.58x indicates conservative capital structure relative to sector peers
ARQT Risks
- Negative operating cash flow of -5.6M and negative FCF of -6.3M demonstrates the company is consuming capital faster than generating it from core operations
- Operating losses at -12.2M with -3.3% operating margin indicate core business is unprofitable and scaling challenges persist
- Inability to cover interest expenses from operations (interest coverage -1.6x) creates refinancing risk and limits financial flexibility
- Anemic 1.1% YoY revenue growth insufficient to offset operating losses and suggests weak market adoption or limited product pipeline success
Key Metrics to Watch
- Operating cash flow trajectory - critical indicator of whether company can reach cash flow breakeven
- Revenue growth acceleration - need to see >15% YoY growth to justify pharmaceutical sector investment thesis
- Path to operating profitability - monitor if operating margin can improve toward 0% within 12-24 months
- Cash burn rate and runway - with 42.9M cash and -5.6M operating cash outflow, company has ~7-8 quarters of runway requiring financing or profitability
ARQT Financial Metrics
ARQT Profitability Ratios
ARQT Balance Sheet & Liquidity
ARQT 5-Year Financial Trend
5-Year Trend Summary: Arcutis Biotherapeutics, Inc.'s revenue has grown significantly by 9,994% over the 5-year period, indicating strong business expansion. The most recent EPS of $-3.78 indicates the company is currently unprofitable.
ARQT Growth Metrics (YoY)
ARQT Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $44.8M | $7.4M | $0.06 |
| Q2 2025 | $30.9M | -$15.9M | $-0.13 |
| Q1 2025 | $21.6M | -$25.1M | $-0.20 |
| Q3 2024 | $8.1M | -$35.4M | $-0.33 |
| Q2 2024 | $4.8M | -$35.4M | $-0.42 |
| Q1 2024 | $2.8M | -$35.4M | $-0.32 |
| Q3 2023 | $725.0K | -$44.8M | $-0.73 |
| Q2 2023 | N/A | -$64.3M | $-1.16 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ARQT Capital Allocation
ARQT SEC Filings
Access official SEC EDGAR filings for Arcutis Biotherapeutics, Inc. (CIK: 0001787306)